ANI Pharmaceuticals, Inc. (ANIP) stock analysis
ANIP · ANI Pharmaceuticals, Inc.
Latest recorded price: USD 70.89
Model-estimated fair value: USD 157.81. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Drug Manufacturers - Specialty & Generic
At $70.89, ANIP trades 55.1% below the model's base-case value of $157.81. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $120.07 in the conservative case and $203.25 in the optimistic case, with a valuation confidence score of 55/100. Fiscal 2025 figures: revenue growth 40.8%, free cash flow margin 19.4%, ROIC 21.0%. The model does not flag any risk signals for this company.
Similar companies in Healthcare
- BioCryst Pharmaceuticals, Inc. (BCRX)
- Bausch Health Companies Inc. Common Stock (BHC)
- Cronos Group Inc. (CRON)
- Elanco Animal Health Incorporated (ELAN)
- Eton Pharmaceuticals, Inc. (ETON)
- Hims & Hers Health, Inc. (HIMS)
- Harrow, Inc. (HROW)
- Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA)